Residency · Residency · Rheumatology

Systemic Lupus Erythematosus - Diagnosis and Classification

Introduction

Systemic lupus erythematosus is the prototypic systemic autoimmune disease, characterized by the production of pathogenic autoantibodies and immune complexes that cause inflammation and damage across virtually every organ system. The prevalence of SLE ranges from 20 to 150 per 100,000 persons, with a striking female-to-male ratio of approximately nine to one during the reproductive years. The disease disproportionately affects Black, Hispanic, and Asian populations, who experience both higher prevalence and greater disease severity. The 2019 EULAR/ACR classification criteria replaced the 1997 ACR criteria, incorporating a weighted scoring system that provides improved sensitivity and specificity and better captures patients with early and incomplete lupus.

Epidemiology and Pathogenesis

Demographics and Risk Factors

SLE typically presents during the peak reproductive years, with the majority of cases diagnosed between ages 15 and 44. Black women experience three to four times the incidence of White women and are more likely to develop severe renal and central nervous system disease. The genetic contribution to SLE susceptibility is substantial, with concordance rates of 24 to 56 percent in monozygotic twins and over 100 risk loci identified through genome-wide association studies. Monogenic forms of lupus, including C1q deficiency, TREX1 mutations, DNASE1L3 mutations, and TLR7 gain-of-function variants, have provided critical insights into the molecular pathways driving disease.

Environmental triggers play an important role in disease initiation and flare. Ultraviolet radiation induces keratinocyte apoptosis and enhances the expression of autoantigens on cell surfaces, directly triggering cutaneous and systemic disease activity. Epstein-Barr virus infection has been epidemiologically and mechanistically linked to SLE development through molecular mimicry and immune dysregulation. Smoking and silica dust exposure are additional environmental risk factors. The hormonal contribution to SLE susceptibility is underscored by the dramatic female predominance during reproductive years, the observation that estrogen promotes B cell survival and autoantibody production, and the finding that males with Klinefelter syndrome (47,XXY karyotype) develop SLE at rates similar to females.

Immunopathogenesis

The immunopathogenesis of SLE involves a cascade of events beginning with defective clearance of apoptotic cells, which exposes nuclear autoantigens to the immune system. Plasmacytoid dendritic cells, activated by nucleic acid-containing immune complexes, produce excessive quantities of type I interferon, creating the interferon signature that is detectable in approximately 50 percent of SLE patients. Loss of B cell tolerance at both central and peripheral checkpoints allows the expansion of autoreactive B cells, which produce the remarkable diversity of autoantibodies described in SLE, with more than 180 different autoantibody specificities identified. Immune complex deposition in target organs activates complement and triggers tissue inflammation and damage. T cell abnormalities, including decreased regulatory T cells, increased T follicular helper cells, and CD4-positive T cell DNA hypomethylation, contribute to the perpetuation of autoimmune responses. Enhanced NETosis with impaired clearance of neutrophil extracellular traps provides an additional source of nuclear autoantigens.

Classification Criteria

2019 EULAR/ACR Classification Criteria

The 2019 EULAR/ACR classification criteria represent a significant advance in the standardized identification of SLE for clinical trials and epidemiologic studies. An entry criterion of an antinuclear antibody (ANA) titer of 1:80 or greater on HEp-2 immunofluorescence assay at any time point serves as a highly sensitive gateway, capturing approximately 98 percent of SLE patients. Once the entry criterion is met, additive weighted criteria across clinical and immunologic domains are applied, with the stipulation that findings should not be counted if they are better attributed to another cause.

The clinical domains and their point values span a wide range. The constitutional domain awards 2 points for fever above 38.3 degrees Celsius. The hematologic domain includes leukopenia below 4000 (3 points), thrombocytopenia below 100,000 (4 points), and autoimmune hemolysis (4 points). The neuropsychiatric domain encompasses delirium (2 points), psychosis (3 points), and seizure (5 points). Mucocutaneous manifestations include non-scarring alopecia (2 points), oral ulcers (2 points), subacute cutaneous or discoid lupus (4 points), and acute cutaneous lupus (6 points). Serosal involvement ranges from pleural or pericardial effusion (5 points) to acute pericarditis (6 points). Joint involvement meeting criteria for synovitis or tenderness with morning stiffness in two or more joints receives 6 points. The renal domain carries the highest possible scores, with proteinuria greater than 0.5 grams per 24 hours receiving 4 points, Class II or V lupus nephritis on biopsy receiving 8 points, and Class III or IV lupus nephritis receiving 10 points.

The immunologic domains include antiphospholipid antibodies (anticardiolipin, anti-beta-2-glycoprotein I, or lupus anticoagulant) at 2 points, low C3 or low C4 at 3 points, both low C3 and low C4 at 4 points, and SLE-specific antibodies (anti-dsDNA or anti-Smith) at 6 points. A total score of 10 or more classifies a patient as having SLE. The 2019 criteria achieve a sensitivity of 96.1 percent and specificity of 93.4 percent.

Comparison with 1997 ACR Criteria

The 1997 ACR criteria required four of eleven criteria to classify a patient as having SLE, with a sensitivity of approximately 83 percent and specificity of approximately 93 percent. The key improvements in the 2019 criteria include the weighted scoring system, which more accurately reflects the diagnostic significance of different manifestations; the inclusion of ANA as an entry criterion; the formal incorporation of complement levels; and the integration of renal biopsy classification. The 2019 criteria are substantially better at classifying patients with early and incomplete lupus.

<image>A scored checklist-style diagram of the 2019 EULAR/ACR SLE classification criteria. Show the entry criterion (ANA ≥1:80) as a gateway, then list all clinical and immunologic domains with their point values in a visually organized format. Use color coding: green for low-weight items (2-3 points), yellow for moderate (4-5 points), and red for high-weight items (6-10 points). Show the threshold line at ≥10 points. Include the highest-scoring item from each domain only (as per the "count highest within each domain" rule). Make it clear that items must not be attributable to other causes.</image>

Autoantibody Testing

ANA (Antinuclear Antibody)

The ANA is the cornerstone screening test for SLE, with a sensitivity of approximately 98 percent when performed by immunofluorescence assay on HEp-2 cells. However, its specificity is limited, as positive results occur in 20 to 30 percent of healthy individuals at low titers and in numerous other conditions. The immunofluorescence pattern provides important diagnostic guidance: a homogeneous pattern is associated with anti-dsDNA and anti-histone antibodies; a speckled pattern with anti-Sm, anti-RNP, anti-Ro, and anti-La antibodies; a nucleolar pattern with anti-RNA polymerase III and anti-Scl-70; and a centromere pattern with limited cutaneous systemic sclerosis. ANA-negative lupus is rare, occurring in fewer than 2 percent of cases, and these patients may have anti-Ro (SS-A) antibodies detectable by more specific assays.

SLE-Specific Antibodies

Anti-double-stranded DNA antibodies have a sensitivity of approximately 60 percent and specificity of approximately 95 percent for SLE. They correlate with disease activity, particularly lupus nephritis, and their titers fluctuate with clinical status, making them valuable for monitoring. Anti-Smith antibodies, with a sensitivity of only approximately 30 percent but a specificity of approximately 99 percent, are the most specific serologic marker for SLE. Unlike anti-dsDNA, anti-Smith levels do not correlate with disease activity. Anti-ribosomal P antibodies are associated with neuropsychiatric SLE, particularly psychosis and depression, with a specificity of approximately 95 percent.

Other Relevant Antibodies

Anti-Ro (SS-A) antibodies are present in approximately 30 percent of SLE patients and are associated with subacute cutaneous lupus, neonatal lupus, and photosensitivity. Anti-La (SS-B) antibodies usually accompany anti-Ro and are associated with Sjogren syndrome overlap; they may confer some protection against nephritis. Anti-RNP antibodies at high titers suggest mixed connective tissue disease, while lower titers are seen in SLE and are associated with Raynaud phenomenon and swollen hands. Anti-histone antibodies are present in more than 95 percent of drug-induced lupus cases and in approximately 50 percent of idiopathic SLE. Anti-C1q antibodies correlate with lupus nephritis activity, and rising titers may predict renal flare. Antiphospholipid antibodies, including anticardiolipin, anti-beta-2-glycoprotein I, and lupus anticoagulant, are present in approximately 40 percent of SLE patients and define those at risk for thrombotic and obstetric complications.

Complement Testing

Complement levels are essential for both diagnosis and monitoring of SLE. C3 and C4 are consumed during immune complex-mediated inflammation, and low levels suggest active disease, particularly nephritis. The CH50, a functional assay of the entire classical complement pathway, may be very low in patients with complement component deficiencies. C4 gene copy number variation, with low copy number, is itself a genetic risk factor for SLE. Complement levels typically normalize with effective treatment and serve as valuable longitudinal biomarkers.

Clinical Manifestations Overview

Mucocutaneous

Cutaneous lupus encompasses three major categories. Acute cutaneous lupus presents as the classic malar or butterfly rash, a symmetric erythematous rash across the cheeks and nose bridge that characteristically spares the nasolabial folds. This rash is photosensitive and occurs in approximately 50 percent of SLE patients. Subacute cutaneous lupus (SCLE) presents as annular polycyclic or papulosquamous lesions, is strongly associated with anti-Ro antibodies, and can be triggered by medications including hydrochlorothiazide, terbinafine, and proton pump inhibitors. Discoid lupus erythematosus (DLE) produces scarring, atrophic plaques with follicular plugging, and only 5 to 10 percent of patients with isolated discoid lupus progress to systemic disease.

Oral and nasal ulcers in SLE are usually painless, with the palate being the most specific location. Non-scarring alopecia may be diffuse or frontal, and the finding of short, broken hairs at the frontal hairline, sometimes termed "lupus hair," is characteristic.

Musculoskeletal

Musculoskeletal involvement affects approximately 90 percent of SLE patients. The arthritis of SLE is typically a non-erosive polyarthritis or polyarthralgia that is symmetric in distribution. Jaccoud arthropathy, characterized by reducible joint deformities including swan neck deformities and ulnar deviation without radiographic erosions, represents a distinctive pattern of chronic lupus joint disease. Avascular necrosis, particularly of the femoral head, is a significant complication whose risk is increased by glucocorticoid use and antiphospholipid antibodies. Myopathy in SLE is usually mild and must be distinguished from steroid myopathy and statin-induced myopathy.

Constitutional

Fatigue is the most common symptom of SLE and often persists even when disease is otherwise well controlled, representing one of the most challenging aspects of management. Fever must always prompt an evaluation for infection, as lupus fever, which typically responds to nonsteroidal anti-inflammatory drugs or low-dose glucocorticoids, is a diagnosis of exclusion. Weight loss and lymphadenopathy may occur but should raise concern for lymphoma, which has an increased incidence in SLE.

<image>A clinical photography-style medical illustration showing the three types of cutaneous lupus side by side on different body regions. Panel A: Acute cutaneous lupus showing the classic butterfly/malar rash across both cheeks and nose bridge, sparing the nasolabial folds, on a female face. Panel B: Subacute cutaneous lupus showing annular polycyclic lesions with raised erythematous borders and central clearing on the upper chest and arms. Panel C: Discoid lupus showing a well-demarcated, erythematous plaque with adherent scale, follicular plugging, central atrophy, and hypopigmentation on the scalp with associated scarring alopecia. Label each type and note key distinguishing features.</image>

General Management Principles

Hydroxychloroquine: Cornerstone of SLE Therapy

Hydroxychloroquine is the single most important medication in the management of SLE, and the 2023 EULAR recommendation states with Level A evidence that all SLE patients should be on HCQ unless specifically contraindicated. The benefits of HCQ are broad and well-documented: it reduces the frequency of disease flares by approximately 50 percent, decreases damage accrual, improves survival, and reduces the risk of thrombosis. Dosing should not exceed 5 milligrams per kilogram of actual body weight per day, a revision from the prior recommendation of 6.5 milligrams per kilogram of ideal body weight, to minimize the risk of retinal toxicity.

The LUMINA cohort demonstrated that HCQ was associated with improved survival independent of other factors. The Hopkins Lupus Cohort showed that HCQ reduces both renal damage and thrombotic events. Retinal toxicity occurs at a rate of approximately 7.5 percent after five years at doses exceeding 5 milligrams per kilogram, and screening per American Academy of Ophthalmology guidelines is essential. Hydroxychloroquine should be continued during pregnancy and breastfeeding, as it is safe and reduces the risk of neonatal lupus.

Disease Activity Monitoring

Systematic assessment of disease activity is fundamental to effective SLE management. The SLEDAI-2K (SLE Disease Activity Index) is a 24-item weighted score in which a value of 6 or greater indicates active disease. The BILAG (British Isles Lupus Assessment Group) index provides organ-specific activity grading from A (most active) to E (never involved). The Physician Global Assessment (PGA) on a 0 to 3 visual analog scale offers a holistic measure of disease status. Laboratory monitoring should include serial assessment of anti-dsDNA titers, C3 and C4 complement levels, complete blood count, urinalysis with microscopy, and urine protein-to-creatinine ratio. The combination of rising anti-dsDNA titers and falling complement levels often precedes a clinical flare and provides an opportunity for preemptive intervention.

General Measures

Sun protection is a critical lifestyle intervention, as ultraviolet radiation is a potent trigger of both cutaneous and systemic lupus activity. Patients should use broad-spectrum UVA/UVB sunscreen with SPF of 50 or greater and wear photoprotective clothing. Smoking cessation is important both because smoking worsens SLE disease activity and because it reduces the efficacy of hydroxychloroquine. Cardiovascular risk management deserves particular attention given the accelerated atherosclerosis that affects SLE patients, necessitating regular screening and management of lipids, blood pressure, and diabetes. Bone health must be addressed, particularly in patients receiving glucocorticoids, with appropriate calcium, vitamin D, and bisphosphonate therapy as needed. Inactivated vaccines are safe for immunosuppressed patients, and COVID-19, influenza, and pneumococcal vaccinations are recommended, while live vaccines should be avoided in patients on immunosuppressive therapy. Reproductive counseling should address contraception planning, with particular attention to avoiding estrogen-containing oral contraceptive pills in patients with antiphospholipid antibodies.

Key Clinical Pearls

• ANA is an entry criterion in the 2019 criteria; a truly ANA-negative patient almost certainly does not have SLE
• Anti-Smith is the most specific antibody for SLE (~99%) but is only ~30% sensitive
• Anti-dsDNA titers and complement levels are the best serologic markers for monitoring disease activity
• Hydroxychloroquine is the only drug proven to improve survival in SLE and should be continued lifelong
• Drug-induced SCLE is increasingly recognized; common culprits include PPIs, thiazides, and terbinafine
• Discoid lupus limited to skin carries only a 5-10% risk of progression to systemic SLE

<image>A diagnostic approach flowchart for suspected SLE. Begin with clinical suspicion (photosensitivity, arthritis, cytopenias, serositis, nephritis), proceed to ANA testing (IFA HEp-2). If ANA positive (≥1:80), proceed to specific antibody panel (anti-dsDNA, anti-Sm, anti-Ro, anti-La, anti-RNP, aPL), complement levels (C3, C4), CBC, urinalysis, and urine protein/creatinine ratio. Apply 2019 EULAR/ACR criteria with scoring. Branch to "≥10 points: classify as SLE" and "<10 points: consider incomplete lupus, UCTD, or alternative diagnosis." For confirmed SLE, show initial workup: echocardiogram if serosal involvement, renal biopsy if proteinuria >0.5g or active sediment, neuroimaging if CNS symptoms. Include a box listing the differential diagnosis (MCTD, drug-induced lupus, viral infection, lymphoma).</image>

References

1. Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412.
2. Fanouriakis A, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.
3. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121.
4. Ruiz-Irastorza G, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus. Ann Rheum Dis. 2010;69(1):20-28.
5. Petri M, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.

Read this lecture as Markdown